disorder

(redirected from Hypoactive sexual desire disorder)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Hypoactive sexual desire disorder: Sexual aversion disorder, HSDD
References in periodicals archive ?
Sexual compatibility and the sexual desire-motivation relation in females with hypoactive sexual desire disorder.
Findings from the pivotal Phase III trials show that flibanserin 100mg is effective and well-tolerated for the treatment of Hypoactive Sexual Desire Disorder in pre-menopausal women," said Elaine Jolly, Medical Director, Shirley E.
Sexual outcomes in Women Treated With Viagra or Placebo Increased Increased Genital Sexual Sensation Satisfaction All women with female sexual Viagra 57% 42% arousal disorder Placebo 44% 28% Women with female sexual arousal disroder but not Viagra 69% 50% hypoactive sexual desire disorder Placebo 41% 21% Source: Laura Berman, Ph.
She reported on a phase lib randomized, double-blind, multicenter trial of 327 women who met diagnostic criteria for hypoactive sexual desire disorder or combined hypoactive sexual desire disorder/female sexual arousal disorder.
The most common form of sexual dysfunction in women is what the American Psychiatric Association's DSM-IV-TR calls hypoactive sexual desire disorder (HSDD).
Sprout), a division of Valeant Pharmaceuticals North America LLC, announced today that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now available in the United States through certified physicians and pharmacies.
And a 2008 research in Obstetrics and Gynecology magazine of 31,000 women age 18 and above found that in the 18 to 44 age group, one in 10 reported low libido, or hypoactive sexual desire disorder (HSDD).
Sexual Outcomes in Women Treated With Viagra or Placebo Increased Increased Genital Sexual Sensation Satisfaction All women with female sexual Viagra 57% 42% arousal disorder Placebo 44% 28% Women with female sexual arousal disorder but not Viagra 69% 50% hypoactive sexual desire disorder Placebo 41% 21% Source: Laura Berman, Ph.
The complaint alleges that during the Class Period, defendants issued materially false and misleading statements regarding the commercial viability, effectiveness, and market potential for LibiGel, a drug designed to improve the sex drive of women suffering from female sexual dysfunction, and specifically hypoactive sexual desire disorder ("HSDD").
The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual desire disorder (HSDD).
According to Stanford University School of Medicine study, women with hypoactive sexual desire disorder (characterized by a continual lack of sexual interest or fantasies) use more brainpower than sexually healthy women in monitoring their reactions and performance during sex.
LibiGel does not achieve primary endpoints in the treatment of hypoactive sexual desire disorder in postmenopausal women